509 related articles for article (PubMed ID: 31075401)
61. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
Stewart AG; Harris PNA; Chatfield MD; Littleford R; Paterson DL
Trials; 2021 Apr; 22(1):301. PubMed ID: 33888139
[TBL] [Abstract][Full Text] [Related]
62. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.
Lee CH; Su LH; Tang YF; Liu JW
J Antimicrob Chemother; 2006 Nov; 58(5):1074-7. PubMed ID: 16971415
[TBL] [Abstract][Full Text] [Related]
63. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
[TBL] [Abstract][Full Text] [Related]
64. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae.
Zohar I; Schwartz O; Yossepowitch O; David SSB; Maor Y
J Antimicrob Chemother; 2020 Feb; 75(2):458-465. PubMed ID: 31691817
[TBL] [Abstract][Full Text] [Related]
65. Impact of a restrictive antibiotic policy on the acquisition of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an endemic region: a before-and-after, propensity-matched cohort study in a Caribbean intensive care unit.
Le Terrier C; Vinetti M; Bonjean P; Richard R; Jarrige B; Pons B; Madeux B; Piednoir P; Ardisson F; Elie E; Martino F; Valette M; Ollier E; Breurec S; Carles M; Thiéry G
Crit Care; 2021 Jul; 25(1):261. PubMed ID: 34311760
[TBL] [Abstract][Full Text] [Related]
66. Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.
Namikawa H; Yamada K; Fujimoto H; Oinuma KI; Tochino Y; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
Intern Med; 2017; 56(14):1807-1815. PubMed ID: 28717075
[TBL] [Abstract][Full Text] [Related]
67. Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?
Bouxom H; Fournier D; Bouiller K; Hocquet D; Bertrand X
Int J Antimicrob Agents; 2018 Jul; 52(1):100-103. PubMed ID: 29580930
[TBL] [Abstract][Full Text] [Related]
68. Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review.
Zhang H; Liang B; Wang J; Cai Y
Int J Antimicrob Agents; 2021 Oct; 58(4):106410. PubMed ID: 34339776
[TBL] [Abstract][Full Text] [Related]
69. Inappropriate empirical antibiotic therapy does not adversely affect the clinical outcomes of patients with acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales.
Kim SH; Oh S; Huh K; Cho SY; Kang CI; Chung DR; Peck KR
Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):937-944. PubMed ID: 30868326
[TBL] [Abstract][Full Text] [Related]
70. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
Kim SA; Altshuler J; Paris D; Fedorenko M
Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
[TBL] [Abstract][Full Text] [Related]
71. Clinical epidemiology, risk factors and treatment outcomes of extended-spectrum beta-lactamase producing Enterobacteriaceae bacteremia among children in a Tertiary Care Hospital, Bangkok, Thailand.
Nivesvivat T; Piyaraj P; Thunyaharn S; Watanaveeradej V; Suwanpakdee D
BMC Res Notes; 2018 Aug; 11(1):624. PubMed ID: 30157960
[TBL] [Abstract][Full Text] [Related]
72. Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae.
Falcone M; Vena A; Mezzatesta ML; Gona F; Caio C; Goldoni P; Trancassini AM; Conti C; Orsi GB; Carfagna P; Stefani S; Venditti M
Ann Ig; 2014; 26(4):293-304. PubMed ID: 25001119
[TBL] [Abstract][Full Text] [Related]
73. Clinical effectiveness of oral antimicrobial therapy for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales.
Kim SH; Lim KR; Lee H; Huh K; Cho SY; Kang CI; Chung DR; Peck KR
Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):159-167. PubMed ID: 31520270
[TBL] [Abstract][Full Text] [Related]
74. Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections.
Tacconelli E; Cataldo MA; Mutters NT; Carrara E; Bartoloni A; Raglio A; Cauda R; Mantengoli E; Luzzaro F; Pan A; Beccara LA; Pecile P; Tinelli M; Rossolini GM
Int J Antimicrob Agents; 2019 Jul; 54(1):49-54. PubMed ID: 30986523
[TBL] [Abstract][Full Text] [Related]
75. Characterisation of extended-spectrum β-lactamase and AmpC β-lactamase-producing Enterobacteriaceae isolated from companion animals in New Zealand.
Karkaba A; Grinberg A; Benschop J; Pleydell E
N Z Vet J; 2017 Mar; 65(2):105-112. PubMed ID: 27973988
[TBL] [Abstract][Full Text] [Related]
76. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
Haruki Y; Hagiya H; Haruki M; Sugiyama T
J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
[TBL] [Abstract][Full Text] [Related]
77. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival.
Balkan II; Aygün G; Aydın S; Mutcalı SI; Kara Z; Kuşkucu M; Midilli K; Şemen V; Aras S; Yemişen M; Mete B; Özaras R; Saltoğlu N; Tabak F; Öztürk R
Int J Infect Dis; 2014 Sep; 26():51-6. PubMed ID: 24998423
[TBL] [Abstract][Full Text] [Related]
78. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.
Rupp ME; Fey PD
Drugs; 2003; 63(4):353-65. PubMed ID: 12558458
[TBL] [Abstract][Full Text] [Related]
79. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
[TBL] [Abstract][Full Text] [Related]
80. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.
Harris PN; Wei JY; Shen AW; Abdile AA; Paynter S; Huxley RR; Pandeya N; Doi Y; Huh K; O'Neal CS; Talbot TR; Paterson DL
J Antimicrob Chemother; 2016 Feb; 71(2):296-306. PubMed ID: 26542304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
